• ML385 and NRF2 Signaling: Evidence and Limits

  2026-10-07

  ML385 is a research-use NRF2 inhibitor used to examine how NRF2-dependent antioxidant signaling influences disease biology. Recent work in inflammatory osteolysis used ML385 alongside genetic and biochemical evidence to test whether kaempferol acts through NRF2. The findings support pathway dependence in that model, but they do not establish clinical efficacy, universal selectivity, or applicability to cancer, ferroptosis, or human disease.

• Phenytoin: A Framework for Sodium-Channel Evidence

  2026-10-07

  Phenytoin research spans voltage-gated sodium channel biology and broader biochemical effects. This evidence-focused guide connects electrophysiology assay design with the reported human serum PON1 inhibition findings while defining appropriate interpretation boundaries.

• Tetracycline: Mechanism, Evidence, and Limits

  2026-10-06

  Tetracycline is a broad-spectrum polyketide antibiotic whose principal activity is reversible bacterial ribosome targeting and inhibition of bacterial protein synthesis. Current evidence supports its microbiological and ribosomal research roles, but the supplied LKB1 lung adenocarcinoma study does not establish tetracycline as a regulator of telomerase or histone lactylation.

• Beyond Calpain Inhibition: From FAK Biology to Translation

  2026-10-06

  The FAISL–calpain 2–FAK axis shows why proteolysis should be treated as a signaling variable rather than a downstream consequence. This thought-leadership article places Calpain Inhibitor II, ALLM within a careful translational framework spanning protease biology, apoptosis, cancer models, evidence boundaries, and biomarker strategy.

• METTL16–SENP3–LTF Drives Ferroptosis Resistance

  2026-10-05

  Wang et al. identify a METTL16–SENP3–LTF signaling axis that links m6A-dependent RNA regulation to iron handling and ferroptosis resistance in hepatocellular carcinoma. The study’s multi-model evidence suggests that this pathway may provide a biomarker framework and a mechanistic basis for sensitizing HCC to ferroptosis-oriented therapeutic strategies.

• Sex Differences in Angiotensin II Hypertension

  2026-10-05

  Xue, Pamidimukkala, and Hay used conscious-mouse telemetry, gonadectomy, baroreflex assessment, and ganglionic blockade to show that angiotensin II produced a substantially larger pressor response in males than females. The study’s main contribution is linking sex-dependent blood-pressure phenotypes with baroreflex and sympathetic mechanisms while defining important limits for interpretation and translation.

• Probenecid: Evidence, Mechanisms, and Limits

  2026-10-04

  Probenecid, also known as 4-(dipropylsulfamoyl)benzoic acid, has been described in research contexts involving organic anion transport, multidrug resistance, pannexin-1 signaling, and cerebral ischemia/reperfusion injury. This overview compares those reported findings with a 2024 study of CD28–ARS2–PKM alternative splicing in CD8+ T cells, while separating direct evidence from mechanistic speculation and identifying important limits on interpretation.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-10-03

  A 2024 bioRxiv preprint shows that some kinase inhibitors can do more than block p38α catalytic activity: they can also accelerate WIP1-mediated dephosphorylation by reshaping the kinase activation loop. Structural and biochemical evidence supports a conformation-directed mechanism, while the preprint’s lack of peer review and limited biological scope define important boundaries for interpretation.

• Calpain Inhibitor II, ALLM: From Protease to Proof

  2026-10-02

  A translational framework for using Calpain Inhibitor II, ALLM to interrogate cysteine protease biology, connect calpain 2–FAK regulation with cancer phenotypes, and distinguish mechanistic evidence from broad protease perturbation.

• PMSF for Protein Extraction and Western Blotting

  2026-10-01

  Phenylmethanesulfonyl fluoride (PMSF) provides fast, irreversible control of serine proteases during tissue, cell, and trophoblast protein extraction. This practical guide connects PMSF for Western blot sample preparation with assay design, RNA–protein workflow separation, and troubleshooting for signaling and developmental biology studies.

• Nifedipine (BAY-a-1040) Research Workflows

  2026-10-01

  Nifedipine (BAY-a-1040) provides a practical perturbation tool for separating L-type calcium signaling from downstream effects on contractility, iron handling, and cell survival. This workflow-focused guide connects calcium influx inhibition with hepatic metabolism studies while defining controls, handling practices, and cross-domain limitations.

• Candida krusei Forms Trigger Distinct BMEC Apoptosis

  2026-09-30

  The 2023 Animals study shows that the yeast and hypha phases of Candida krusei induce bovine mammary epithelial cell apoptosis through different dominant signaling routes. Its co-culture design links morphology-specific injury to mitochondrial, death receptor, TLR, ERK, and JNK signaling, providing a framework for more selective mechanistic studies of fungal mastitis.

• DiscoveryProbe™ Protease Inhibitor Library Guide

  2026-09-30

  Learn how SKU L1035 can support reproducible protease activity modulation, viability testing, apoptosis assays, and mechanistic screening. This scenario-based guide covers assay compatibility, protocol parameters, data interpretation, and practical supplier selection for biomedical laboratories.

• AMG 9810 TRPV1 Antagonist Workflow

  2026-09-29

  Use AMG 9810 to separate TRPV1-dependent calcium entry and CGRP secretion from broader metabolic-stress effects. This workflow combines concentration-response pharmacology, sensory-neuron readouts, and carefully controlled AMPK–SQSTM1 context experiments.

• Rotenone: Mitochondrial Complex I Inhibitor

  2026-09-29

  Rotenone is a mitochondrial Complex I inhibitor used to induce controlled electron-transport stress, ATP loss, ROS elevation, and neuronal injury. Its value in apoptosis, autophagy pathway research, and Parkinson's disease model workflows depends on concentration, cell state, solvent controls, and orthogonal validation.

7846 records 1/524 page Next 12345 下5页 Last page